S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Marker Therapeutics Stock Price, News & Analysis (NASDAQ:MRKR)

$2.76
0.00 (0.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$2.69
▼
$2.76
50-Day Range
$2.40
▼
$4.81
52-Week Range
$0.67
▼
$9.68
Volume
8,756 shs
Average Volume
19,467 shs
Market Capitalization
$24.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability

MRKR stock logo

About Marker Therapeutics Stock (NASDAQ:MRKR)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

MRKR Stock Price History

MRKR Stock News Headlines

November 20, 2023 | msn.com
Community dedicates Blue/Gold Star Hwy Marker
November 15, 2023 | businesswire.com
Sales Marker Introduces AI Sales to the World
December 2, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 10, 2023 | msn.com
Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M
November 9, 2023 | morningstar.com
Marker Therapeutics Inc MRKR
November 9, 2023 | finance.yahoo.com
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023 | msn.com
Blue Star Memorial Highway Marker dedication set for Nov. 9 in Wrightsville Beach
November 4, 2023 | msn.com
Jackrabbits run past Bison, Marker stays in Brookings
December 2, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 4, 2023 | msn.com
Dakota Marker dominance: Jackrabbits cruise over North Dakota State
November 4, 2023 | msn.com
Live Blog: #1 SDSU hosts #11 NDSU in Dakota Marker matchup
November 3, 2023 | msn.com
NDSU vs SDSU Dakota Marker Rivalry Game Bobbleheads revealed
November 3, 2023 | msn.com
SDSU vs. NDSU Dakota Marker football rivalry bobblehead unveiled
November 3, 2023 | msn.com
Flashback Friday: The first Dakota Marker
November 1, 2023 | msn.com
SDSU preps for Dakota Marker vs. NDSU
October 31, 2023 | msn.com
A&M United Methodist Church to receive State Historical Marker Dedication on Nov. 1
October 22, 2023 | msn.com
Delaware football live report: Marker steps in for injured O'Connor, Hens up 31-0 early
October 21, 2023 | msn.com
Delaware football live report: Marker steps in for injured O'Connor, Hens up 14-0
October 17, 2023 | usnews.com
Historical Marker Planned to Honor Students Who Integrated Mississippi University for Women
October 14, 2023 | health.usnews.com
Nicole Marker-Zewe
October 13, 2023 | news.yahoo.com
Okeechobee resident Carol Marker to compete in Special Olympics tennis tournament
October 11, 2023 | finance.yahoo.com
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
October 10, 2023 | msn.com
Anantara The Marker — where Dublin’s It crowd hang out
October 2, 2023 | usnews.com
Black Man's 1845 Lynching in Downtown Indianapolis Recounted With Historical Marker
September 19, 2023 | usnews.com
Making a Mark: London’s Historic Blue Plaques Seek More Diversity as 1,000th Marker Is Unveiled
September 11, 2023 | finance.yahoo.com
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
September 9, 2023 | msn.com
Browns unveil Ohio Historical Marker honoring famous 'Cleveland Summit' that featured Muhammad Ali, Jim Brown
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRKR
CUSIP
N/A
CIK
1094038
Web
www.markertherapeutics.com
Phone
(713) 400-6400
Fax
N/A
Employees
67
Year Founded
2018

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,930,000.00
Net Margins
-77.33%
Pretax Margin
-158.82%
Return on Equity
-98.22%
Return on Assets
-62.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.01
Quick Ratio
7.01

Sales & Book Value

Annual Sales
$9.01 million
Price / Sales
2.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.88 per share
Price / Book
1.47

Miscellaneous

Outstanding Shares
8,890,000
Free Float
6,747,000
Market Cap
$24.54 million
Optionable
Not Optionable
Beta
1.37

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Juan F. Vera M.D. (Age 43)
    Co-Founder, CEO, President & Director
    Comp: $529.12k
  • Mr. Eliot M. Lurier CPA (Age 65)
    Interim Chief Financial Officer
  • Ms. Elizabeth Donnelly
    Director of Administration
  • Mr. Edmund Cheung
    Vice President of Human Resources
  • Dr. Nadia Agopyan Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Monic Stuart M.D.
    Chief Medical Officer
  • Mr. Gerald Garrett
    Senior Vice President of Clinical Operations
  • Mr. Michael J. Loiacono (Age 57)
    Treasurer & Secretary
    Comp: $287.98k
  • Dr. Robert Z. Florkiewicz Sr.
    Senior Director of Molecular Biology & Virology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions














MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed in 2023?

Marker Therapeutics' stock was trading at $0.2659 at the beginning of 2023. Since then, MRKR shares have increased by 938.0% and is now trading at $2.76.
View the best growth stocks for 2023 here.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our MRKR earnings forecast.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its earnings results on Thursday, November, 9th. The company reported ($0.34) earnings per share for the quarter. The business had revenue of $0.26 million for the quarter. Marker Therapeutics had a negative trailing twelve-month return on equity of 98.22% and a negative net margin of 77.33%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Matrix Asset Advisors Inc. NY (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Norman David Eansor, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRKR) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -